Hans P. Hartung

Duesseldorf, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Journal: Frontiers in immunology

Published: March 17, 2026

Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy.

Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy.

Journal: Annals of clinical and translational neurology

Published: February 27, 2025

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.

Journal: Drugs in R&D

Published: July 11, 2023

Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages.

Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages.

Journal: Qatar medical journal

Published: January 25, 2023

The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.

The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.

Journal: Multiple sclerosis and related disorders

Published: February 09, 2022

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.

Journal: Multiple sclerosis and related disorders

Published: November 23, 2020

Secretome Analysis of Mesenchymal Stem Cell Factors Fostering Oligodendroglial Differentiation of Neural Stem Cells In Vivo.

Secretome Analysis of Mesenchymal Stem Cell Factors Fostering Oligodendroglial Differentiation of Neural Stem Cells In Vivo.

Journal: International journal of molecular sciences

Published: May 25, 2020

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination.

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination.

Journal: Glia

Published: June 07, 2018

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: January 23, 2018

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Journal: The Lancet. Neurology

Published: August 17, 2017

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.

Journal: Multiple sclerosis and related disorders

Published: June 30, 2016

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.

Journal: PloS one

Published: June 16, 2016

Showing 1-12 of 26

Last Updated: 09/26/2026